Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin

被引:860
作者
Morgenthaler, NG [1 ]
Struck, J [1 ]
Alonso, C [1 ]
Bergmann, A [1 ]
机构
[1] BRAHMS AG, Dept Res, Ctr Biotechnol, Neuendorfstr 25, D-16761 Berlin, Germany
关键词
D O I
10.1373/clinchem.2005.060038
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Arginine vasopressin (AVP) is a key regulator of water balance but its instability makes reliable measurement difficult and precludes routine use. We present a method for quantifying AVP release by use of copeptin, a glycopeptide comprising the C-terminal part of the AVP prohormone. Methods: We measured copeptin in 50-mu L serum and plasma samples from healthy individuals and from critically ill patients with sepsis. Our sandwich immunoluminometric assay used 2 polyclonal antibodies to amino acids 132-164 of pre-provasopressin. Results: The assay yielded results within 3 h. The analytical detection limit was 1.7 pmol/L, and the interlaboratory CV was < 20% for values > 2.25 pmol/L. The assay was linear on dilution of the analyte. Ex vivo copeptin siability (< 20% loss of analyte) for at least 7 days at room temperature and 14 days at 4 degrees C was shown for serum and EDTA-, heparin-, and citrate plasma. Copeptin (median, 4.2 pmol/L; range, 1-13.8 pmol/L) was detectable in 97.5% of 359 healthy individuals and was not associated with age. Median concentrations were considerably higher in men than women, increased significantly after exercise, and were influenced by fasting and water load. Copeptin was significantly (P < 0.001) increased in 60 critically ill patients with sepsis (median, 79.5 pmol/L; range, 10.6-228.0 pmol/L). The correlation between copeptin and AVP for 110 samples was r = 0.78 (P < 0.0001). Conclusions: Copeptin is stable for days after blood withdrawal and can be quickly and easily measured.
引用
收藏
页码:112 / 119
页数:8
相关论文
共 27 条
[1]   Properties of human vasopressin precursor constructs: Inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes [J].
Barat, C ;
Simpson, L ;
Breslow, E .
BIOCHEMISTRY, 2004, 43 (25) :8191-8203
[2]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[3]   Structure-function relationships of the vasopressin prohormone domains [J].
de Bree, FM ;
Burbach, JPH .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 1998, 18 (02) :173-191
[4]   Clinical review:: Vasopressin and terlipressin in septic shock patients [J].
Delmas, A ;
Leone, M ;
Rousseau, S ;
Albanèse, J ;
Martin, C .
CRITICAL CARE, 2005, 9 (02) :212-222
[5]   Arginine vasopressin in advanced vasodilatory shock -: A prospective, randomized, controlled study [J].
Dünser, MW ;
Mayr, AJ ;
Ulmer, H ;
Knotzer, H ;
Sumann, G ;
Pajk, W ;
Friesenecker, B ;
Hasibeder, WR .
CIRCULATION, 2003, 107 (18) :2313-2319
[6]  
GINES P, 1994, SEMIN NEPHROL, V14, P384
[7]   GLYCOPEPTIDE FROM POSTERIOR LOBE OF PIG PITUITARIES .1. ISOLATION AND CHARACTERIZATION [J].
HOLWERDA, DA .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1972, 28 (03) :334-&
[8]   Usefulness of plasma N-terminal proatrial natriuretic peptide (proANP) as an early predictor of outcome in unstable angina pectoris or non-ST-elevation acute myocardial infarction [J].
Jernberg, T ;
Stridsberg, M ;
Lindahl, B .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (01) :64-+
[9]  
Kluge M, 1999, CLIN CHEM, V45, P98
[10]  
Landry DW, 1997, CIRCULATION, V95, P1122